Table of Contents
The Department of Veterans Affairs and the Department of Health and Human Services signed a memorandum of understanding in July 2026 to expand psychedelic therapy research and ready the VA for potential use of FDA-approved treatments. The partnership targets veterans with serious mental illness, a population HHS Secretary Kennedy estimated at roughly one million people.
- An inter-agency agreement, not a treatment program: The memorandum of understanding formalizes cooperation between the VA and HHS; it does not itself approve or deliver any therapy to veterans.
- Scale of need cited: HHS Secretary Kennedy stated that nearly six million veterans live with mental illness or substance use disorders, with approximately one million carrying a serious mental illness diagnosis.
- Research acceleration is the stated goal: The partnership is described as a move to speed psychedelic therapy research and to prepare VA infrastructure for treatments that may eventually receive FDA approval.
- No therapy is currently VA-approved: The agreement anticipates possible future FDA-approved psychedelic treatments; no such treatment is approved or available through the VA as of the signing date.
- Model
- human
- Sample
- Policy announcement; no clinical trial participants enrolled
- Design
- Memorandum of understanding between the U.S. Department of Veterans Affairs and the U.S. Department of Health and Human Services, signed July 13, 2026
- Key outcome
- Formalized inter-agency cooperation to accelerate psychedelic therapy research and prepare VA for potential future FDA-approved treatments
- Main limitation
- This is a policy agreement, not a clinical study; no efficacy or safety data are reported
What the Research Examined
This recap is drawn from a Military.com news report published July 13, 2026, which describes a policy announcement rather than a peer-reviewed clinical trial. The source is treated here as commentary on an underlying government action: the signing of a memorandum of understanding between the Department of Veterans Affairs and the Department of Health and Human Services at VA headquarters in Washington, D.C. VA Secretary Doug Collins and HHS Secretary Robert F. Kennedy Jr. signed the agreement. Because no primary study document, DOI, or clinical trial registration number was provided in the source, the citation below links to the Military.com article.
The memorandum is framed around a documented public health need. Secretary Kennedy cited figures suggesting that close to six million veterans currently live with some form of mental illness or substance use disorder, and that roughly one million of those veterans carry a serious mental illness diagnosis. Those figures are asserted in the source as Kennedy’s own statements; the report does not identify the underlying data set. The agreement commits the two agencies to expand cooperative research and to build VA capacity for treatments that might one day receive FDA approval, placing this move squarely within the broader landscape of federal psychedelic policy developments now unfolding at the agency level.
It is worth being precise about what this agreement does and does not do. A memorandum of understanding is an administrative instrument that structures inter-agency collaboration. It does not approve any compound for clinical use, does not enroll veterans in a treatment program, and does not indicate that any specific psychedelic therapy has cleared FDA review for veterans. The announcement signals institutional intent and resource alignment, which is meaningful at the policy level, while the therapeutic science continues to develop through separate clinical research channels.
What the Findings Show
- Veterans with mental illness or substance use disorders.HHS Secretary Kennedy stated that nearly six million veterans currently live with mental illness or substance use disorders, according to the Military.com report.
- Veterans with serious mental illness.Of that broader population, Kennedy cited approximately one million veterans as living with a serious mental illness, the group the partnership most directly targets.
- Agreement type.The two agencies signed a memorandum of understanding, a formal but non-binding coordination instrument, not a funding bill or regulatory action.
Because the source is a news article describing a policy event, there are no clinical outcome numbers, effect sizes, or trial results to report. The figures cited above come from Secretary Kennedy’s public statements as quoted by the outlet and have not been independently verified in this recap against primary VA or HHS data sources.
What did the VA and HHS psychedelic therapy partnership actually agree to do?
The two agencies signed a memorandum of understanding to coordinate research efforts and prepare VA systems for possible future FDA-approved psychedelic treatments. No treatment has been approved or made available through the VA yet. The agreement is a structural step, not a clinical program.
What This Is, and What It Is Not
This is This is a report on a federal policy announcement, not a peer-reviewed clinical study, and no trial data, dosing information, or patient outcomes are available from this source.
This is not This recap is not evidence that psychedelic therapy is currently available through the VA, and it should not be read as medical advice or as confirmation that any specific compound is safe and effective for veterans. Anyone seeking mental health support should consult a qualified clinician.
Our Take
For those of us who hold these medicines as sacred, watching federal agencies move toward formal cooperation on psychedelic research carries weight that goes beyond politics. Veterans have carried wounds that conventional psychiatry has often struggled to reach, and many in our community have witnessed, quietly and outside any official system, how these substances can open doors that seemed permanently closed. A memorandum is not a cure, and we hold realistic expectations: the road from inter-agency agreement to accessible, culturally sensitive care is long. But the fact that two cabinet-level departments are now formally coordinating on this work, citing a population of one million people with serious mental illness who need better options, is a sign that the conversation is moving from the margins toward the center, and that is worth noting with sober gratitude.
If you or someone you love is a veteran navigating the space between where conventional care ends and something new has not yet begun, you are not alone in that threshold. This community exists precisely for that in-between place. Grounding and Integration are not abstract stations on a map; they are the daily work of making meaning from what has been carried. We welcome you to explore what we have gathered here, ask the questions that feel too large for a clinical waiting room, and move at whatever pace feels honest. The door is open.
Frequently Asked Questions
Is psilocybin therapy now available to veterans through the VA?
No. The memorandum of understanding signed in July 2026 is a research and coordination agreement. No psychedelic therapy has received FDA approval for veteran care or been made available through VA facilities as of the date of this announcement.
What does a memorandum of understanding between the VA and HHS actually do?
It formally commits two federal agencies to share resources, coordinate research efforts, and build institutional readiness. It is an administrative instrument, not a law, a funding allocation, or a treatment authorization.
How many veterans are affected by serious mental illness according to this announcement?
HHS Secretary Kennedy cited roughly one million veterans living with serious mental illness, within a broader figure of nearly six million veterans with some form of mental illness or substance use disorder. These are his stated figures; the source does not identify the underlying dataset.
Which psychedelic compounds does the VA and HHS partnership focus on?
The Military.com source refers broadly to psychedelic therapies and does not specify individual compounds. The agreement is framed around treatments that may eventually receive FDA approval, without naming psilocybin, MDMA, or any other specific substance.
Is this partnership the same as a clinical trial for veterans?
No. The announcement describes an inter-agency policy agreement to accelerate research and prepare VA infrastructure. A clinical trial would involve a separate protocol, enrolled participants, oversight board approval, and a registered study design.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
